Skip to main content
. 2024 May 16;38(7):1522–1533. doi: 10.1038/s41375-024-02278-8

Fig. 2. Cumulative BCR::ABL1IS ≤1% by time point in patients with baseline BCR::ABL1IS > 1%a.

Fig. 2

Cumulative BCR::ABL1IS ≤1% in all evaluable patients (A) overall, (B) by BCR::ABL1IS at baseline, and (C) by prior treatment with ponatinib. IS International Scale. a Treatment discontinuations for any reason were treated as competing events.